Conventional systemic and topical treatments have proven ineffective for the treatment of onychomycosis caused by Neoscytalidium dimidiatum. Our aim was to evaluate the effectiveness and safety of laser monotherapy for the treatment of onychomycosis caused by this pathogen. Patients with clinical onychomycosis of the toenails and positive results both on direct mycological examination and N. dimidiatum culture underwent four 1064 nm Nd:YAG laser sessions with 6-week intervals between sessions. Participants were monitored by clinical examination supported by dermoscopy, measurement of diseased nail and the onychomycosis severity index (OSI), and by mycological examination for 12 months after completion of treatment. Treatment outcome was based on clinical and laboratory criteria and was divided in complete or partial cure, clinical improvement, treatment failure and relapse. No patient had complete or partial cure at any time during the study. Clinical improvement was observed in 40.6% of the patients at the end of the laser sessions; however, it did not persist during the follow-up. Treatment failure was observed in 64.7% of the patients at the end of 12 month follow-up period. Direct microscopy and culture results remained positive in most patients. Adverse events, in addition to treatment-related pain, were observed and considered severe in one case. The 1064 nm Nd:YAG laser was not able to cure onychomycosis caused by N. dimidiatum but temporarily improved the clinical appearance of the nail; however, adverse events may occur.
Introduction
The 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser was the first type of laser approved by the Food and Drug Administration (FDA) for temporary improving nail appearance of chronic onychomycosis caused by dermatophytes. Afterward, diode, CO 2, and other laser devices came into use for the same purpose. Most studies report that the use of lasers for onychomycosis is safe, effective, and free of significant adverse events, except tolerable pain and heat, and therefore superior to conventional therapy. [1] [2] [3] The clinical similarity of onychomycosis caused by dermatophytes and by Neoscytalidium dimidiatum led our group to investigate if light-based therapies might be an alternative for this emerging pathogen since currently, no treatment is considered the gold standard in the scientific literature. 4 The fungus N. dimidiatum, a soil saprobe and plant pathogen, causes superficial lesions on the nail, palmoplantar, and interdigital regions. Systemic infection cases have been reported. In some cases, previous chronic skin and/or nail lesions existed, which may indicate a potential reservoir of this microorganism in immunosuppressed patients. 5 This was a study intended to evaluate the effectiveness and safety of using a laser device as monotherapy for the treatment of onychomycosis caused by N. dimidiatum.
Methods
This was a prospective, uncontrolled, nonrandomized, open-label study conducted at the Department of Dermatology of the Pedro Ernesto University Hospital (Hospital Universitário Pedro Ernesto [HUPE]), Rio de Janeiro State University (Universidade do Estado do Rio de Janeiro [UERJ]), Brazil, and approved by the Research Ethics Committee of the HUPE/UERJ in 2013. All patients signed the informed consent form after their questions were answered.
The inclusion criteria were as follows: patients with a clinical diagnosis of onychomycosis in at least one hallux and direct microscopy and culture results that were both positive for N. dimidiatum; age older than 18 years; and no use of topical antifungal medication for at least one month or systemic medication for at least three months. Pregnant and lactating women and patients with severe noncontrolled systemic disease were excluded.
The most affected hallux was chosen as the target nail for evaluation of all clinical and laboratory parameters of the protocol. Clinical evaluation was performed by observing the nail apparatus with the aid of a handheld dermatoscope and digital photographs. The percentage of longitudinal damage of the nail plate was measured and ranked as <25%, 25-50%, 51-75%, or >75%, in addition to the previously described onychomycosis severity index (OSI). 6 This method is generally used to assess the prognosis and to choose the appropriate therapy for onychomycosis, and is calculated by multiplying the score of the nail affected area by the score of the proximity of the disease to the nail matrix. If dermatophytoma (in our case, dermatophytomalike) and/or subungual keratosis >2.0 mm is present the score is increased in 10 points (OSI = area × matrix proximity + 10). Onychomycosis is considered as mild, moderate, or severe if total OSI is 1-5, 6-15, or 16-35, respectively. Due to the lack of a standard method to measure the area of involvement, our group developed a more objectively guide for this calculation (Fig. 1) . Clinical evaluation was performed before and after treatment and at 12 months after its completion. When involvement of the palmoplantar and interdigital regions was noted, the patient was advised to apply 1% butenafine cream q.d. for 6 weeks.
Direct microscopy, clarified with KOH+DMSO, was considered positive when septate, hyaline or dematiaceous hyphae and/or arthroconidia were present on the skin scales of subungual scrapings. Culture was considered positive when N. dimidiatum was isolated on Sabouraud dextrose agar (SDA) and identified by its colony with a cotton-like disorganized surface and a micromorphology showing hyaline and/or brownish septate hyphae and dark brown, thickwalled conidia with one or two septa. Mycological examinations were performed before and after treatment and at 12 months post-treatment.
Laser treatment consisted of four sessions with an interval of approximately 6 weeks between sessions. The device used was a 1064 nm Nd:YAG laser (Genesis TM , Cutera, Inc., USA) with the following parameters: fluence of 16 J/cm 2 , 0.3 millisecond pulse duration, spot size of 5 mm, and a 2-3 Hertz repetition rate. Four laser cycles were applied in each session, with an average of 400 passes for the target nail and 400 passes for all other affected nails, resulting in up to 800 passes per foot. The entire nail plate was intermittently treated in a spiral pattern, as previously described. 7 All affected toenails were treated by advancing approximately 2.0 mm toward the periungual, lateral, and proximal edges. A digital thermometer was used to measure the temperature.
The following healing criteria were considered to measure the outcome of the laser treatment for onychomycosis at the end of the four laser sessions and at 12 months posttreatment:
Complete cure: clinically healthy nail, direct microscopy and culture both negative; Partial cure: less than 25% of the longitudinally nail damaged and direct microscopy and culture both negative; Mycological cure: both direct microscopy and culture negative, independent of nail clinical appearance. Clinical improvement: improvement compared to the initial examination, but with direct microscopy and/or culture positive. Treatment failure: nail identical to or worse than pretreatment and/or direct microscopy and/or culture positive. Recurrence/relapse: after achieving complete or partial cure presents clinical worsening and/or direct microscopy and/or culture positive results.
Microsoft Excel 2010 and R version 3.2.3 were used for statistical analysis and a significance level of P < .05 was adopted. The log-rank test was used to evaluate possible significant differences in the distribution of onychomycosis duration and patient age in relation to the therapeutic outcome. Student t test was used to determine statistical differences in the OSI throughout the study.
Results
In the period between June 2013 and September 2014 (16 months), the Mycology Laboratory of HUPE/UERJ diagnosed 64 patients with onychomycosis caused by N. dimidiatum. Of these, 36 patients were included in the study because they met the pre-established inclusion/exclusion criteria, including 26 (72.2%) females and 24 (67.7%) individuals of nonwhite ethnicity. The mean age was 60.8 years, ranging from 42 to 81 years. Thirty-two patients (89%) completed the four laser applications established in the protocol, and 17 (47.2%) completed the study. The reasons for protocol drop-out were concomitant diseases not related to the treatment, treatment failure, and a severe adverse event related to laser use in one patient.
Among the comorbidities of these patients, the most common were heart disease in 23 (63.8%) and dyslipidemia in 10 (27.7%) patients. Four (11%) patients with palmar lesions, 14 (39%) with plantar lesions, and 13 (36%) with lesions in the interdigital region used butenafine cream. In 25 (75%) patients, more than one nail was affected. The mean duration of disease was 8.6 years, ranging from 4 months to 20 years.
All 36 patients presented with the distal/lateral type of onychomycosis. Onycholysis (100%), yellow nail discoloration (94.4%), and subungual keratosis >2.0 mm (97%) were the most common clinical findings.
Of the 36 patients who participated in the protocol 36.2% presented with a longitudinal damage of the nail plate between 25 and 50% and 30.5% between 51 and 75%. The majority of the patients were considered to have a severe OSI (67%) before treatment. According to the mean numerical score of the OSI, no significant improvement was observed at the end of the four laser applications or at the end of follow up (P > .05). Table 1 shows the results of treatment progression based on these parameters.
On direct microscopy, dematiateous hyphae were present in two patients and brownish arthroconidia were noted in 10. The remaining samples showed hyaline fungi structures. Mycological cure, defined as both negative direct microscopy and culture, was achieved by a single patient at treatment end and by another one at 12 months post-treatment. By these time points, both patients did not show any clinical improvement. Direct microscopy was positive in 87.5% and 94.5%, respectively, at the end of laser sessions and at 12 month follow-up. Culture remained positive in 56.2% samples at the end of treatment and in 66.7% at 12 months post-treatment. Neoscytalidium dimidiatum phenotype on SDA alternated between hyaline and dematiateous in the patient's samples during the study period.
Approximately 90% of patients complained of moderate or severe pain during laser application. The measured temperature during application ranged between 40.9
• C and 56.5
• C, depending on individual tolerance. Reports of erythema, periungual blisters, and discomfort for up to a week between sessions, followed by nail loss, were noted. Nail surface peeling with a wave pattern appearance (Fig. 2a) , onychomadesis (Fig. 2b) , and hematoma were also observed. Patients reported of pain relief when onychocryptosis was present. We noticed an immediate darkening of the nail, similar to a burn, during the procedure on one patient (Fig. 2c) . A persistent nail plaque scar was observed in one patient after laser session (Fig. 2d-e) . One patient developed partial necrosis of the hallux and a scar caused by the laser. According to the clinical and laboratory criteria for cure adopted in this study, no patient had complete or partial cure. At the end of the four laser sessions, 13 (40.6%) of the 32 patients exhibited clinical improvement, and 19 (59.4%) had treatment failure. At the end of the 18 months of the study, six (35.3%) of the 17 patients who continued in the study showed clinical improvement, and 11 (64.7%) had treatment failure (Fig. 3a-f) . No statistically significant evidence was found to indicate that age (p = 0.266) or the duration (P = .186) of onychomycosis affected the therapeutic outcome.
Discussion
Neoscytalidium dimidiatum is one of the nondermatophyte moulds that causes onychomycosis and is commonly found in tropical countries; in certain areas it replaces dermatophytes. 9 This microorganism is usually resistant to conventional treatments, leading to a chronic and mainly relapsing disease with financial implications to the public health system in countries in which it is endemic, which are predominantly developing countries. 10 Clinicians and mycologists should be aware of changes in the epidemiology of N. dimidiatum due to the recent people immigration from areas where it might be endemic, like north of Africa and Syria. Case reports or series of published cases show partial results or no results with conventional treatments, although isolated reports of cure have been noted. The treatments used include 5% amorolfine and 8% ciclopirox nail lacquers or systemic medications such as terbinafine, itraconazole, posaconazole, and voriconazole. [11] [12] [13] [14] The association of mechanical, surgical, or chemical intervention is recommended to increase the penetration of topical medicines. Nondermatophyte moulds therapy is normally based on dermatophytosis used drugs or procedures. Considering specifically N. dimidiatum, some investigators were not able to cure patients combining treatment with oral terbinafine and 8% ciclopirox nail lacquer or with the latter alone. The only patient to obtain complete cure relapsed after 6 months. 4 A 50% of complete cure was reported in 28 patients treated with 5% amorolfine nail lacquer, twice a week, for approximately 180 days. 11 In another study, a patient was treated with photodynamic therapy (PDT) using methyl aminolevulinate and a light-emitting diode (LED) lamp in four sessions. The patient achieved clinical and mycological cure; however, N. dimidiatum was isolated again after a 6-month follow-up, showing once more the high recurrence rate of this etiologic agent. 15 A different study demonstrated that N. dimidiatum was more sensitive to treatment with a 1064 nm Nd:YAG laser than T. mentagrophytes. The authors achieved a cure rate of 66.7% at 6 months follow up using a different Nd:YAG 1064 nm laser device (Dualis SP, Fotona, Slovenia), in four sessions 1 week apart. Parameters used were 35-40 J of fluence, 1 Hz frequency, pulse duration of 30-35 ms, and a 4-mm spot size. Cure was defined as negative fungal culture (no direct microscopy) and residual subungual hyperkeratosis or onycholysis less than 10%. 16 Unlike these previous studies carried out in different geographic regions, in our work, no patient was cured, and the clinical improvement obtained in 40.6% of the 32 patients at the end of the four laser sessions in 6 months was only temporary and was not maintained throughout the 12 months of follow-up. Possible explanations for the differences between previous researches and ours may include the type of population studied, molecular and phylogenetic differences in N. dimidiatum isolates, fungus virulence, and consequently host-parasite interaction, or even the use of more stringent criteria for assessing outcomes along with different scientific methods. Moreover, the choice of using a device for onychomycosis usually is based on the lack of response or contraindications to conventional drugs so that patients commonly present with more severe and chronic nail disease and this was the case with the current study. Elucidation about laser mechanisms of action for the treatment of onychomycosis is still lacking; in vitro and in vivo studies have shown conflicting results regarding mechanism of action of laser over fungi. Some of the hypotheses already published are the heat fungicidal action over the fungi, keratin proteins denaturation, the possible laser influence on cellular oxidative reactions, changes in host immune modulation or even the laser energy absorption by xantomegnin and melanin, chromophores of T. rubrum and N. dimidiatum, respectively. [17] [18] [19] [20] A cutaneous murine model already developed for the study of N. dimidiatum skin infections might be relevant in analyzing some of the proposed theories. 21 Likewise, there is no gold standard for laser treatment, such as the best laser device, the optimal number of treatment sessions, and the interval between them; therefore, clinical trials are still needed. More rigorous and standardized scientific guidelines are desirable to compare the results, like well-defined clinical and mycological outcomes and the time points when these are measured. [22] [23] Pharmacological trials typically have more defined rules to measure the treatment outcomes and a longer follow up than do device trials which are crucial when expanding studies results. It could be that our study provides a more realistic picture of the treatment efficacy in N. dimidiatum onychomycosis since we have more suitably defined time points and outcomes than previous device trials. In some reports, the OSI has been used to monitor the therapeutic outcome for onychomycosis, although it was originally proposed for prognosis and therapy selection. The large score variation among the three degrees of severity (mild, moderate, and severe) affects the statistical evaluation for the study outcome; however, isolated use of the numeric score can be valuable index. Currently, dermoscopy of the nail apparatus (onychoscopy) is an indispensable semiological resource for evaluation of nail diseases, facilitating not only the diagnosis but also assisting with the detection of important clinical signs. In a published study the authors found the "ruins aspect" of the subungual keratosis only in patients with onychomycosis, a dermoscopic sign also present in our patients. 24 Considering that the FDA approved this treatment for temporary clinical improvement and not to cure the disease or as monotherapy, thus far it is necessary that other treatments are prescribed in combination with the laser. Treatments that target only the nails usually have low cure and high relapse rates because, among other reasons, they do not treat the adjacent skin lesions, such as plantar and interdigital lesions, which are the likely fungus reservoir for invading the nail through the hyponychium. Approximately one-third of our patients had adjacent skin lesions, which were likely the source of nail infection. The mycological examination remained positive in most patients, demonstrating the ineffectiveness of this laser to treat onychomycosis caused by N. dimidiatum.
A positive aspect of the treatment was the feeling of aesthetic improvement by the patient, which was mainly due to lightening of the nail plate with consequent improvement in self-esteem.
Most published studies claim that laser treatment for onychomycosis is safe and effective, showing not only temporary improvement but also a high percentage of cure of the disease. However, our study, similar to others, failed to reproduce those results. 20, [25] [26] [27] More adverse events were observed in the present research than in most published studies. [28] [29] [30] Onychomadesis seems to be a consequence of the reported blisters on periungual folds. Reports of the feeling of local discomfort for up to one week after laser application were noted. Nail peeling with a wave pattern was a common clinical observation and appears to be a result of intermittent and temporary injury of the nail matrix at the site where the laser was also applied, approximately 2.0 mm from the periungual edges. The feeling of pain and burning caused by the laser energy in the nail plate is still one of the problems of the treatment, which often has to be interrupted due to patient discomfort. N. dimidiatum is a black fungus and therefore has a greater amount of target (melanin) for this laser beam. Furthermore, an in vitro study showed that this fungus also requires higher temperatures, for a longer time, than dermatophytes for elimination. That would not be tolerated by the patient. 20 Two severe adverse events were reported in the literature. In one study, a diabetic patient developed blisters and was hospitalized and amputated. 31 In the other study, one of our patients, developed necrosis, and had, as a consequence, a scar sequela. 8 Patients with peripheral neuropathy withstand higher temperatures without reporting pain or burning. Treatment of onychomycosis with a laser was not effective or fully safe, with occurrence of mild to severe adverse events. To date, no scientific evidence exists to support the use of a laser as a first choice for single or combined treatment of onychomycosis although it might be an alternative attempt in very special situations.
